The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to grow at a CAGR of 10.2% to reach USD 19.7 billion by 2034. Market expansion is being fueled by a ...

Asimov will use its CHO Edge System to develop a high-titer cell line for Kaigene’s novel multispecific antibody that selectively degrades pathogenic antibodies.BOSTON, Aug. (GLOBE NEWSWIRE) -- Asimov ...

Cell line development is an essential step in the manufacture of biologics: drugs derived from living organisms, such as monoclonal antibodies, recombinant proteins and vaccines. In addition to this, ...

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability, and ...

Cell line development is a crucial step in the drug discovery and development pipeline. It is essential in the manufacturing of biologics, as well as for drug screening, disease modeling and studying ...

Over the past decade, biologics development has moved from artisanal experimentation to a data-driven, platform-based discipline. Analytical depth has improved. Process integration has matured. Yet ...

Cell line development continues to face technical and operational hurdles in transfection, clone selection, and media optimization. Manual screening, extended culture timelines, and fragmented data ...

From Fluidic Sciences and Sphere BioReviewed by Olivia Frost This article is based on a poster originally authored by Maryam Ahmadi, Elena Shvets, Frank Gesellchen, Xin Liu, Jessica Hall and Richard ...

Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Kaigene, a ...